The Anlon Healthcare IPO has reached its third and final day of bidding, drawing strong interest across investor categories. With steady demand and a stable grey market premium (GMP), investors are now weighing whether this IPO is a good long-term opportunity or just a short-term play.
Day 3 Subscription Status
As of the morning session on 29 August 2025, the IPO had received solid participation:
- Overall subscription: ~3.9×
- Retail quota: Subscribed nearly 27×
- Non-Institutional Investors (NIIs): Around 3.2×
- Qualified Institutional Buyers (QIBs): Just over 1×
The enthusiasm from retail investors clearly outpaces institutional demand, showing strong public confidence in the issue.
Grey Market Premium (GMP) Trends
The IPO’s GMP is holding steady at ₹6, suggesting an expected listing price of ₹96–97 per share against the upper price band of ₹91.
This points to a modest premium of 5–6%, which indicates that while blockbuster listing gains may not be on the cards, investors see the IPO as a stable bet.
Expert Opinions – Positives and Risks
Supportive Views
- Analysts highlight strong sectoral tailwinds from government policies like Make in India and PLI schemes, which boost domestic API (Active Pharmaceutical Ingredient) producers.
- The company’s product portfolio and regulatory approvals provide a foundation for future growth.
Cautionary Views
- Heavy reliance on a single manufacturing plant in Rajkot is seen as a risk.
- Valuation looks stretched with a P/E of ~19× and EV/EBITDA of ~16–17×, leaving limited margin of safety.
- Listing gains may be capped due to already high demand from retail bidders.
Brokerage Take
Some research houses have recommended a “Subscribe for Long Term” stance, underlining growth potential but advising against chasing short-term profits alone.
Quick IPO Snapshot
| Factor | Detail |
|---|---|
| Issue Period | Closes on 29 August 2025 |
| Price Band | ₹86–91 per share |
| Overall Subscription | ~3.9× (till Day 3 morning) |
| Retail Subscription | ~27× |
| NII Subscription | ~3.2× |
| QIB Subscription | ~1× |
| GMP | ₹6 |
| Likely Listing Price | Around ₹96–97 |
| Analyst View | Good for long-term investors; cautious for short-term traders |
Final Verdict – Good or Bad Bet?
- For long-term investors: The IPO could be a smart addition, supported by industry growth drivers and solid fundamentals, though valuations are on the higher side.
- For listing gains: With a GMP of just ₹6, expectations of big first-day profits should be tempered.
In short, Anlon Healthcare IPO looks better suited for patient, long-term investors who believe in India’s expanding pharmaceutical manufacturing story, rather than those chasing quick short-term returns.
